NPPB and chronic kidney disease: A recent prospective cohort study nested within the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) has reported that troponin T and NT-proBNP enhance prediction of ESRD outcomes, including death, beyond established risk factors, eGFR, and proteinuria in type 2 diabetic patients with CKD and anaemia [18].